search
Back to results

Pilot Study on Device-assisted Mobilisation of Critically Ill Patients (LIANA-I)

Primary Purpose

Muscle Weakness, Critical Illness

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Device-assisted mobilisation with the sit/stand stabilizer Liana
Sponsored by
Charite University, Berlin, Germany
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Muscle Weakness focused on measuring ICUAW, Muscle Weakness

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Intensive care patient with ventilatory support and an expected intensive care stay of at least another 48 h Age ≥ 18 years Current length of intensive care stay < 48 h Exclusion Criteria: Moribund and critically ill Suspected 6-month mortality > 75%. Increased intracranial pressure Critically ill after cardiopulmonary resuscitation Critically ill with primary neuromuscular disease or motor neuron disease One or more amputated extremities Patients, within 2h after surgery Unstable fractures Severe traumatic brain injury (e.g., brain and skull injuries) Circulatory instability with norepinephrine > 0.3 µg/kg/min Patients for whom there is an indication for deep sedation (RASS -5) Language barrier Fitting of legs into leg trays is not possible due to e.g. patient weight

Sites / Locations

  • Charité - Univiversitätsmedizin BerlinRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention Group

Control Group

Arm Description

Mobilization incl. support by the Liana. In the intervention group, Liana is used to train trunk stability in a sitting position. If this is successful, the patient is trained to stand. Mobilization to higher levels is performed according to clinical standards.

Standard of Care without the use of the Liana. In the control group the therapy is carried out according to the ward standard without using the Liana.

Outcomes

Primary Outcome Measures

Level of mobilisation (IMS)
Mean level of mobilisation measured with the Intensive Car Unit Mobility Scale (IMS) till ICU discharge (or Day 28); IMS ranges from 0 (no mobilization) to 10 (independent walking)

Secondary Outcome Measures

Frequency of IMS ≥ 4
Frequency of Days with IMS ≥ 4 till ICU discharge (or Day 28)
Handgrip strength
Muscle strength measured using handgrip strength till ICU discharge (or Day 28)
MRC Sum Score
Muscle strength measured using Medical Research Council (MRC) Sum Score till ICU discharge (or Day 28); MRC Sum Score ranges from 0 to 60, with 0 worst value
Diaphragma function
Diaphragm function by diaphragmatic thickening fraction using ultrasound till ICU discharge (or Day 28)
CPAx Score
The Chelsea Critical Care Physical Assessment Tool (CPAx) during the ICU stay (or till Day 28); ranging from 0 to 50 with 0 the worst score
Trunk Control Test
Trunk stability using the trunk control test during the ICU stay (or till Day 28)
Duration of MV
Duration of mechanical ventilation (MV) in days
Patient satisfaction with VRS
Patient satisfaction with mobilisation using a verbal rating scale (VRS 0-10), 0 the worst score
Staff satisfaction with VRS
Staff satisfaction with mobilisation using a verbal rating scale (VRS 0-10), 0 being worst score
Staff binding time
Staff binding time for mobilisation during the ICU stay (or Day 28)
ICU LOS
ICU length of stay in Days
Hospital LOS
Hospital length of stays
Time in rehabilitation and hospital
Time in rehabilitation facilities or hospital in days
(I)ADL
(Intrumental) Activities of Daily Living Score as measured by Iwashyna et al.; range 0-11, 0 the worst
Disability
Disability measured with the WHODAS 2.0 score
Quality of life
Quality of life measured with the EQ-5D-5L. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Detail information is available at https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/
Physical Function
Physical function measured with the Barthel Score, scoring from 0-100 with 0 the worst

Full Information

First Posted
January 28, 2023
Last Updated
September 6, 2023
Sponsor
Charite University, Berlin, Germany
search

1. Study Identification

Unique Protocol Identification Number
NCT05716451
Brief Title
Pilot Study on Device-assisted Mobilisation of Critically Ill Patients
Acronym
LIANA-I
Official Title
Randomised Pilot Study on Device-assisted Mobilisation With a Sit/Stand Stabiliser of Critically Ill Patients With Ventilatory Support
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 27, 2023 (Actual)
Primary Completion Date
December 30, 2024 (Anticipated)
Study Completion Date
July 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Charite University, Berlin, Germany

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This Pilot study will hypothesize that patients with organ insufficiency and breathing assistance in our post-anaesthesia care unit (PACU) and ICU will be mobilized more often to an ICU mobility scale (IMS) ≥ 4 (i.e. standing) using the Liana® mobilizer. Therefore a randomized controlled pilot study will be conducted. The aim is to achieve an important physical function mile stone more often using this device. Secondary hypotheses are: The intervention will relieve the burden of the health care staff in the unit The intervention will positively influence the functional outcome of critically ill patients The intervention is perceived as positive by the patients
Detailed Description
Patients who have been treated in the ICU for a prolonged period of time often have a high degree of immobility. In this context, a state of generalized weakness associated with muscle atrophy (ICUAW) develops in approximately 40% of ICU patients. The severity of generalized weakness may be individual in each patient. It is certain that especially elderly patients and patients with prolonged immobilization have an increased incidence of ICUAW. Symptoms can be highly variable depending on the severity of the course. Some patients report weakness of the extremities to paresis and weakness of the respiratory muscles. Weakness of the respiratory musculature can lead to a prolonged weaning process of mechanical ventilation, prolonging the stay in the ICU. Functional impairments due to ICUAW may also persist many years after the ICU stay. If ICUAW is diagnosed promptly, outcome can be improved by targeted early mobilization. Early mobilization is defined as mobilization in the first 72 h from ICU admission. However, there are numerous barriers to the implementation of early mobilization in critically ill patients, so this remains a major challenge. Various studies have shown that patients can benefit from a high level of mobilization. For example, Scheffenbichler et al. showed that a high dose of mobilization was associated with increased independence of patients after discharge. The level of mobilization showed positive effects not only in this study, but also in Paton and colleagues. They were able to show that achieving a higher level of mobility (according to the Intensive Care Mobility Scale) was associated with improved outcome at six months. They found that achieving a higher level of mobilization positively affected the health status of patients, whereas increasing the number of mobilizations did not. With device-assisted mobilization, patients could be mobilized to standing position early and more frequently. The aim of this pilot study is to test whether mobilization of critically ill patients with ventilatory support using device-assisted mobilization leads to increased mobilization to standing (IMS 4) or beyond.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Weakness, Critical Illness
Keywords
ICUAW, Muscle Weakness

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
Mobilization incl. support by the Liana. In the intervention group, Liana is used to train trunk stability in a sitting position. If this is successful, the patient is trained to stand. Mobilization to higher levels is performed according to clinical standards.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Standard of Care without the use of the Liana. In the control group the therapy is carried out according to the ward standard without using the Liana.
Intervention Type
Device
Intervention Name(s)
Device-assisted mobilisation with the sit/stand stabilizer Liana
Intervention Description
Non-invasive device-assisted mobilisation with LIANA
Primary Outcome Measure Information:
Title
Level of mobilisation (IMS)
Description
Mean level of mobilisation measured with the Intensive Car Unit Mobility Scale (IMS) till ICU discharge (or Day 28); IMS ranges from 0 (no mobilization) to 10 (independent walking)
Time Frame
28 Days
Secondary Outcome Measure Information:
Title
Frequency of IMS ≥ 4
Description
Frequency of Days with IMS ≥ 4 till ICU discharge (or Day 28)
Time Frame
28 Days
Title
Handgrip strength
Description
Muscle strength measured using handgrip strength till ICU discharge (or Day 28)
Time Frame
28 Days
Title
MRC Sum Score
Description
Muscle strength measured using Medical Research Council (MRC) Sum Score till ICU discharge (or Day 28); MRC Sum Score ranges from 0 to 60, with 0 worst value
Time Frame
28 Days
Title
Diaphragma function
Description
Diaphragm function by diaphragmatic thickening fraction using ultrasound till ICU discharge (or Day 28)
Time Frame
28 Days
Title
CPAx Score
Description
The Chelsea Critical Care Physical Assessment Tool (CPAx) during the ICU stay (or till Day 28); ranging from 0 to 50 with 0 the worst score
Time Frame
28 Days
Title
Trunk Control Test
Description
Trunk stability using the trunk control test during the ICU stay (or till Day 28)
Time Frame
28 Days
Title
Duration of MV
Description
Duration of mechanical ventilation (MV) in days
Time Frame
180 Days
Title
Patient satisfaction with VRS
Description
Patient satisfaction with mobilisation using a verbal rating scale (VRS 0-10), 0 the worst score
Time Frame
28 Days
Title
Staff satisfaction with VRS
Description
Staff satisfaction with mobilisation using a verbal rating scale (VRS 0-10), 0 being worst score
Time Frame
28 Days
Title
Staff binding time
Description
Staff binding time for mobilisation during the ICU stay (or Day 28)
Time Frame
28 Days
Title
ICU LOS
Description
ICU length of stay in Days
Time Frame
180 Days
Title
Hospital LOS
Description
Hospital length of stays
Time Frame
180 Days
Title
Time in rehabilitation and hospital
Description
Time in rehabilitation facilities or hospital in days
Time Frame
180 Days
Title
(I)ADL
Description
(Intrumental) Activities of Daily Living Score as measured by Iwashyna et al.; range 0-11, 0 the worst
Time Frame
180 Days
Title
Disability
Description
Disability measured with the WHODAS 2.0 score
Time Frame
180 Days
Title
Quality of life
Description
Quality of life measured with the EQ-5D-5L. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Detail information is available at https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/
Time Frame
180 Days
Title
Physical Function
Description
Physical function measured with the Barthel Score, scoring from 0-100 with 0 the worst
Time Frame
180 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Intensive care patient with ventilatory support and an expected intensive care stay of at least another 48 h Age ≥ 18 years Current length of intensive care stay < 48 h Exclusion Criteria: Moribund and critically ill Suspected 6-month mortality > 75%. Increased intracranial pressure Critically ill after cardiopulmonary resuscitation Critically ill with primary neuromuscular disease or motor neuron disease One or more amputated extremities Patients, within 2h after surgery Unstable fractures Severe traumatic brain injury (e.g., brain and skull injuries) Circulatory instability with norepinephrine > 0.3 µg/kg/min Patients for whom there is an indication for deep sedation (RASS -5) Language barrier Fitting of legs into leg trays is not possible due to e.g. patient weight
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stefan J Schaller, MD
Phone
+49-30-450-5311052
Email
stefan.schaller@charite.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan J Schaller, MD
Organizational Affiliation
Charite University, Berlin, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Charité - Univiversitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan J Schaller, MD
Phone
+49-30-450-5311052
Email
stefan.schaller@charite.de

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
The plan is to share deidentified data by reasonable scientific request and after signing an appropriate agreement.

Learn more about this trial

Pilot Study on Device-assisted Mobilisation of Critically Ill Patients

We'll reach out to this number within 24 hrs